Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Takikita, Mikiko ^a   Xie, Ran ^a   Chung, Joon Yong ^a   Cho, Hanbyoul ^a   Ylaya, Kris ^a   Hong, Seung Mo ^b   Moskaluk, Christopher A ^c   Hewitt, Stephen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; CANCER ANTIBODY; HER2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; TISSUE TYPES; WESTERN BLOTTING; CELL MEMBRANE; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960885569     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-126     Document Type: Article

References (48)

1. Society AC Cancer Facts and Figures 2003. Atlanta, GA 2003, Society AC.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001, 345:1890-1900. 10.1056/NEJMra001375, 11756581.
3. Olayioye M, Neve R, Lane H, Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167. 10.1093/emboj/19.13.3159, 313958, 10880430.
4. Hynes N, Lane H. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354. 10.1038/nrc1609, 15864276.
5. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004, 306:1506-1507. 10.1126/science.1105396, 15567848.
6. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287. 231527, 8816440.
7. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
8. Adams G, Weiner L. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23:1147-1157. 10.1038/nbt1137, 16151408.
9. Shawver L, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123. 10.1016/S1535-6108(02)00039-9, 12086869.
10. Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat K, Moasser M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441. 10.1038/nature05474, 3025857, 17206155.
11. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007, 29:655-664. 10.1002/hed.20574, 17315173.
12. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008, 15:1193-1201. 10.1245/s10434-007-9771-3, 18172732.
13. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
14. Soulieres D, Senzer N, Vokes E, Hidalgo M, Agarwala S, Siu L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22:77-85.
15. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22:1646-1654. 10.1200/JCO.2004.03.089, 15117987.
16. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi O. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
17. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999, 17:1983-1987.
18. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003, 95:851-867. 10.1093/jnci/95.12.851, 12813169.
19. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174. 10.1056/NEJMra0707704, 18337605.
20. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007, 357:1496-1506. 10.1056/NEJMoa071167, 17928597.
21. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
22. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002, 98:833-837. 10.1002/ijc.10257, 11948459.
23. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998, 55:548-555. 10.1159/000011911, 9778622.
24. D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G, Summerhayes IC. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 1989, 4:1233-1239.
25. Kearsley JH, Leonard JH, Walsh MD, Wright GR. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991, 23:189-194. 10.3109/00313029109063564, 1685773.
26. Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, Gapany S, Gluckman JL. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992, 12:2273-2276.
27. Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992, 12:613-619.
28. Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR. Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 1997, 17:4539-4546.
29. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999, 5:4164-4174.
30. Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res 2000, 20:997-1004.
31. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000, 12:229-239. 10.1097/00001622-200005000-00008, 10841195.
32. Shiga H, Rasmussen AA, Johnston PG, Langmacher M, Baylor A, Lee M, Cullen KJ. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck 2000, 22:599-608. 10.1002/1097-0347(200009)22:6<599::AID-HED9>3.0.CO;2-M, 10941162.
33. Werkmeister R, Brandt B, Joos U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 2000, 36:100-105. 10.1016/S1368-8375(99)00069-X, 10889928.
34. Hoffmann TK, Ballo H, Braunstein S, Van Lierop A, Wagenmann M, Bier H. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol 2001, 37:50-56. 10.1016/S1368-8375(00)00056-7, 11120483.
35. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
36. Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley S, Tidy A, Harrison S. Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes 1987, 1:383-391. 10.1016/0890-8508(87)90019-3, 3330998.
37. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996, 16:5276-5287. 231527, 8816440.
38. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000, 126:205-211. 10.1007/s004320050034, 10782893.
39. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297. 10.1002/path.1370, 12845624.
40. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 2008, 14:7843-7849. 10.1158/1078-0432.CCR-08-1064, 19047113.
41. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004, 91:1532-1542. 10.1038/sj.bjc.6602184, 2410019, 15480434.
42. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002, 196:17-25. 10.1002/path.1003, 11748637.
43. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008, 10:R2. 10.1186/bcr1843, 2374953, 18182100.
44. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007, 96:801-807. 10.1038/sj.bjc.6603613, 2360069, 17299391.
45. Fetsch PA, Abati A. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagn Cytopathol 2007, 35:319-328. 10.1002/dc.20638, 17497656.
46. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007, 31:493-499.
47. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer I, Gebhard S, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006, 24:4317-4323. 10.1200/JCO.2005.04.8397, 16896008.
48. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006, 6:46. 10.1186/1471-2407-6-46, 1431553, 16507107.